Latest
finance.yahoo.com Earnings
Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
The study met its primary and all secondary endpoints at Week 24 Rapid onset of clinical activity was observed with significant improvements as early as Week 4 Durable clinical activity demonstrated following single-dose administration, supporting 6- month dosing for the treatment of CRSwNP '512 was well tolerated across all dosing groups '512 granted Breakthrough Therapy Designation in China …
Main company
🇭🇰 Hong Kong
Read at finance.yahoo.com